{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '7.5.6.3.', 'Serious Adverse Events and Adverse Events of Special Interest Require', 'Immediate Reporting to Sponsor/Designee', 'An assessment of the seriousness of each AE will be made by the Investigator. Any AE and', 'laboratory abnormality that meets the SAE criteria in Section 7.5.6.1 and any AESI must be', 'reported to the Sponsor or designee within 24 hours from the time that clinical study center staff', 'first learns of the event. All SAEs must be reported regardless of the relationship to IMP.', 'The initial report should include at least the following information:', \"Patient's study number\", 'Description and date of onset of the event', 'Criterion for serious', 'Preliminary assignment of relationship to IMP, and', 'Investigator/site information', 'To report the SAE, complete the SAE form. Within 24 hours of receipt of follow-up', 'information, the Investigator must update the SAE form. Serious AEs must be reported using the', 'contact information provided in the Study Manual.', 'Appropriate remedial measures should be taken by the Investigator using his/her best medical', \"judgment to treat the SAE. These measures and the patient's response to these measures should\", 'be recorded. All SAEs, regardless of relationship to IMP, will be followed by the Investigator', 'until satisfactory resolution or the Investigator deems the SAE to be chronic or stable. Clinical,', 'laboratory, and diagnostic measures should be employed by the Investigator as needed to', 'adequately determine the etiology of the event.', '7.5.6.4.', 'Sponsor Safety Reporting to Regulatory Authorities', 'The Sponsor or its representative will report certain study events in an expedited manner to the', \"Food and Drug Administration, the European Medicines Agency's EudraVigilance electronic\", 'system according to Directive 2001/20/EC, and to all country Regulatory Authorities where the', 'study is being conducted, according to local applicable regulations.', '7.5.6.5.', 'Serious Adverse Event Notification to the Institutional Review', 'Board/Independent Ethics Committee', 'Suspected unexpected serious adverse reactions (SUSARs) will be reported to the IRB/IEC per', 'their institutional policy by the Investigator or Sponsor (or Sponsor designee) according to', 'country requirements. Copies of each report and documentation of IRB/IEC notification and', \"acknowledgement of receipt will be kept in the Investigator's study file.\", '7.5.6.6.', 'Pregnancy Reporting', 'There will only be male patients in this study.', 'The reporting of any pregnancy outcome for a female partner of a male patient participating in', 'this study that results in a postpartum complication, spontaneous abortion, stillbirth, neonatal', 'death, or congenital anomaly should be reported to the Investigator, who will then report this to', 'Property of the Sanofi Group - strictly confidential', '64', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'the Sponsor or designee. The pregnancy outcome is to be recorded on the pregnancy reporting', 'form.', '7.5.6.7.', 'Overdose Reporting', 'An overdose is defined as any dose administered to or taken by a patient (accidentally or', 'intentionally) that exceeds the highest daily dose, or is at a higher frequency than included in the', 'protocol. Overdose must be recorded in the eCRF.', 'All reports of overdose (with or without an AE) must be reported within 24 hours to the Sponsor', 'or designee.', '7.5.6.8.', 'Guidelines for Reporting Product Complaints/Medical Device Incidents', '(Including Malfunctions)', 'Any defect in the IMP must be reported as soon as possible by the Investigator to the monitoring', 'team that will complete a product complaint form within required timelines.', 'Appropriate information (eg, samples, labels, or documents like pictures or photocopies) related', 'to product identification and to the potential deficiencies may need to be gathered. The', 'Investigator will assess whether or not the quality issue has to be reported together with an AE or', 'SAE.', '7.6.', 'Other Assessments', '7.6.1.', 'Patient-reported Outcomes', 'Patient-reported outcomes will be utilized in this study where available to assess health-related', 'quality of life (HRQOL), physical activity, and treatment satisfaction and health utility. The age', 'of the patient at randomization will determine which age-specific questionnaires will be utilized,', 'and will be in force for the study duration. All completed questionnaires or instrument forms for', 'the patient-reported outcome assessments described below will be collected, entered into a', 'database, and archived according to the Study Manual.', 'The Sponsor or designee will provide the translations for all survey instruments, where', 'translations are available. The sites must not translate any survey instruments.', '7.6.1.1.', 'HRQOL Instruments: Haem-A-QOL and Haemo-QOL', 'The Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) and Hemophilia', 'Quality of Life Questionnaire for Children and Adolescents (Haemo-QOL) are psychometrically', 'tested QOL assessment instruments for patients with hemophilia.[1 The Haem-A-QOL will be', 'provided to patients >17 years of age, and includes 46 items contributing to 10 QOL domains', '(physical health, feelings, view of yourself, sports and leisure, work and school, dealing with', 'hemophilia, treatment, future, family planning, partnership and sexuality). Scoring for each item', 'is based on a 5-point Likert scale (never, rarely, sometimes, often, and all the time), and higher', 'scores represent greater impairment.', \"The Haemo-QOL (Children's short version for age groups II/III [8-16 years of age]) will be\", 'provided to patients <17 years of age, to self-complete as specified in the Schedule of', 'Property of the Sanofi Group - strictly confidential', '65', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}